Anti-Mouse CD70 (Clone FR70) – Purified in vivo GOLD™ Functional Grade

BALB/c mouse B lymphoma A20.J2

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

IP
B
FC
For specific conjugates of this clone, review literature for suggested application details.

FR70 activity is directed against mouse CD70.

Mouse CD70 is transiently expressed on the surfaces of antigen-activated B and T cells, natural killer cells, and mature dendritic cells. CD70 is also aberrantly expressed on malignant cancer cells.

CD70, a type II transmembrane glycoprotein of the TNF family with cytokine activity, is the ligand for the CD27 receptor¹. Mouse CD70 (mCD70) has a potent co-stimulatory effect on T cell proliferation¹ and acts as an immune-checkpoint². In mouse, but not in humans, the CD70-CD27 axis mediates a negative feedback system that enables the immune system to modulate hematopoiesis². Additionally, CD70-CD27 interactions are important to the formation of memory and plasma B cells. Immunotherapies that aim to eradicate tumor cells by targeting CD70 overexpression are being developed². FR70 inhibits mCD70 binding to mCD27-Ig, a recombinant soluble form of mCD27¹, as well as to mCD27 in vitro^3,4 and in vivo⁵. FR70 was produced by immunizing an F344/DuCrj rat with A20 cells and fusing the splenocytes with P3U1 cells to create hybridoma lines¹. HAT selection was performed, and FR70 was identified by its strong reactivity against mCD70-BHK21 cells. Blocking with FR70 can prolong graft acceptance^6,7. When mouse cardiac allogenic graft recipients are treated with FR70, tolerogenic dendritic cells and T regulatory cells are induced, resulting in decreased cytotoxic T lymphocyte proliferation as well as long-term graft acceptance⁶. Blocking with FR70 also prolongs mouse corneal graft survival⁷.

CD27

T-B cell cross-stimulation

1. Oshima H, Nakano H, Nohara C, et al. Int Immunol. 10(4):517-526. 1998.
2. Flieswasser T, Van den Eynde A, Van Audenaerde J, et al. J Exp Clin Cancer Res. 41(1):12. 2022.
3. Mahmud SA, Manlove LS, Schmitz HM, et al. Nat Immunol. 15(5):473-481. 2014.
4. Kuka M, Munitic I, Giardino Torchia ML, et al. J Immunol. 191(5):2282-2289. 2013.
5. Ballesteros-Tato A, León B, Lee BO, et al. Immunity. 41(1):127-140. 2014.
6. Zhao J, Que W, Du X, et al. Front Immunol. 11:555996. 2021.
7. Narimatsu A, Hattori T, Usui Y, et al. Exp Eye Res. 199:108190. 2020.
8. Wensveen FM, Unger PP, Kragten NA, et al. J Immunol. 188(9):4256-4267. 2012.
9. Tewalt EF, Cohen JN, Rouhani SJ, et al. Blood. 120(24):4772-4782. 2012.
10. Ho PC, Meeth KM, Tsui YC, et al. Cancer Res. 74(12):3205-3217. 2014.